Senti Biosciences Publishes New Peer-Reviewed Research In Cell Systems Demonstrating Its Systematic Framework For Engineering NOT-Gated Chimeric Antigen Receptor Circuits In Both T Cells And Natural Killer Cells

Senti Biosciences, Inc. (Nasdaq: SNTI) has published new peer-reviewed research in Cell Systems, outlining a systematic framework for engineering NOT-gated chimeric antigen receptor (CAR) circuits in T cells and natural killer (NK) cells. The study highlights the potential of Logic-Gated receptor designs to enhance the efficacy and safety of cell therapies by allowing immune cells to target tumor cells while protecting healthy tissue. This research complements Senti's recent positive clinical data for its Logic-Gated SENTI-202 product in treating relapsed/refractory Acute Myeloid Leukemia.